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Surgical aortic valve replacement (SAVR) has 
been a standard of care for patients with severe 
aortic stenosis (SAS) with excellent procedural 
outcomes, low complication rates and acceptable 
valve durability when bioprostheses were used. 
However, many patients with SAVR indication did 
not undergo surgery worldwide due to high surgi-
cal risk or many other not well-known reasons [1].
Moreover, outstanding surgical outcomes 
cannot be replicated in every single center doing 
SAVR around the globe.
Transcatheter aortic valve replacement 
(TAVR) was introduced by Dr Cribier, as an alter-
native to extreme risk patients 14 years ago [2]. 
After initial development, TAVR was tested against 
the standard treatment for inoperable patients and 
SAVR in well-conducted randomized clinical trials; 
using the 2 most studied currently available TAVR 
devices.
Out of these trials we have learned that TAVR 
is superior to medical treatment including balloon 
aortic valvuloplasty for inoperable patients. It is 
necessary to treat only 5 patients to save 1 life 
within a year. Thus, TAVR becomes a standard 
treatment for anatomically suitable patients suf-
fering from symptomatic SAS [3, 4].
For those patients with life expectancy shorter 
than 1-year or extremely deteriorated physical 
condition precluding benefit from TAVR, the con-
cept of futility was introduced [5]. With that, a new 
concern has arisen, and patients requiring TAVR 
should be excluded from this treatment because 
a poor benefit is expected based on the heart team 
evaluation.
TAVR was also tested in those patients with 
high surgical risk in 2 randomized clinical trials 
(RCT) showing similar outcomes to SAVR in the 
PARTNER trial and superiority in the US Pivotal 
CoreValve study. After these outcomes were pre-
sented TAVR was considered an alternative to SAVR 
for this population, the high cost being the main 
limitation for its wide use in most countries [6, 7].
Although TAVR was initially introduced for 
high-risk patients, many intermediate risk cases 
were treated and reported worldwide. Meanwhile, 
2 big RCT (PARTNER II and SURTAVI trial) were 
conducted [8]. Also, there are several registries 
and matched comparisons showing that TAVR has 
better outcomes in these groups of patients, which 
are similar and better than SAVR in some cases. 
The lower the risk, the better the outcomes.
In this regard, the NOTION trial evaluated 
a combined primary endpoint including any death, 
myocardial infarction or stroke at 1 year, which 
was similar for TAVR and SAVR (13.1% vs. 16.3%; 
p = 0.43). SAVR-treated patients had more major 
bleeding, new onset atrial fibrillation and cardio-
genic shock, while TAVR patients had more aortic 
regurgitation and they need more permanent 
pacemaker implantation.
However, there is still no consensus about 
treating these intermediate risk patients in the 
routine clinical practice, especially when young. 
Nevertheless, different subgroups may be consid-
ered among them, being the octogenarians without 
other co-morbidities; probably the first subset that 
may benefit from the TAVR use expansion, because 
initial outcomes have been probed and durability is 
no longer an issue for this population, after 5-year 
follow-ups have been reported.
Beyond big RCT there are several series and 
registries reflecting the real life practice and show-
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ing quite similar outcomes with those found in the 
aforementioned randomized clinical studies [9–11].
Device durability has been a concern issue 
from the beginning of the experience, but we 
have now some data in this regard to downgrade 
this concern. PARTNER 5-year follow-up showed 
consistence on outcomes over time, despite the 
high mortality rate observed in both groups mainly 
due to baseline conditions in the inoperable group 
(mean survival was 11.1 months for standard 
therapy and 29.7 months for TAVR treatment; 
p < 0.0001). Re-hospitalization was also higher in 
the standard treatment arm. The 5-year survival 
in the PARTNER A group was 40.6 months for 
SAVR and 44.5 months for TAVR group; p = NS 
[12]. A recently published 2-year follow-up of 
the CoreValve US Pivotal showed even better 
outcomes compared with 1-year, because there 
was an increase in the reduction of mortality from 
1st to 2nd years of the follow-up (4.9 to 6.5 percentage 
points) in favor of TAVR compared with the surgical 
arm and becoming significant (p = 0.04). A similar 
continued divergence was seen in the stroke rates 
of 6.5% at 1 year to 8.9% at 2 years [13].
An Italian multicenter registry including 
353 patients who received a third-generation Core-
Valve with a 5-year follow-up showed similar mor-
tality rate to RCT; a late prosthesis failure occurred 
in 1.4% of cases. Ten (2.8%) patients showed late 
mild stenosis with a mean transaortic gradient 
ranging from 20 to 40 mm Hg [14].
This low valve deterioration rate over the 
5–7 years is in agreement with other presentations. 
However, there are many pending questions, such 
as: can these outcomes be considered a class ef-
fect?; are they similar to different vascular access?; 
and, would be these outcomes similar to new 
devices that are being introduced on the market?
Regarding periprocedural complications, the 
higher stroke rate observed in the TAVR group 
of the PARTNER trial was worrisome [15]. How-
ever, those findings were not corroborated by the 
US Pivotal study using the self-expanding device. 
Moreover, stroke rate was lower in the TAVR 
group, and for some not well-explained reasons this 
difference was wider at 2nd year favoring TAVR. In 
the same way, all registries were showing a trend 
for better clinical outcomes and lower complica-
tions rate, including stroke — probably due to more 
experienced operators and better devices [16].
Furthermore, a multicenter registry using 
CoreValve without pre-dilation showed lower 
stroke rate in comparison to those patients who 
received valvuloplasty before device implantation 
showing that technique is also important. In our 
series of CoreValve cases without pre-dilation 
(n = 165), we have an any stroke rate of 2.4% 
(1.2% major stroke). Additionally, some studies 
using cerebral protection devices and subrogate 
endpoints showed promising findings regarding 
less micro- and macro-embolization when cerebral 
protection was used [17–20].
It is also important to know that preoperative 
neurocognitive status seems to be kept at 2 years 
after TAVR [21].
With a better technique, the need of PPM 
implantation has been reduced but still remains 
high for self-expanding device. The good news is 
that PPM implantation after TAVR does not have 
clinical consequences on long-term follow-up with 
the self-expandable valve and most of the regis-
tries; but not in a subanalysis of the PARTNER 
trial, which showed longer hospital stay, more 
re-hospitalization and mortality for those who 
received PPM [22].
New devices with lower profile, refinement on 
patient selection and more experienced operators 
may decrease vascular complication, one of the 
major predictors of perioperative mortality in the 
initial series, leading also the femoral approach to 
be the most commonly used by far in the current 
practice.
Thus, femoral approach using closure devices 
paved the way to use local anesthesia under sedation 
or neuroleptoanalgesia, transthoracic echo guidance 
with provisional transesophageal echocardiography 
for a so called “minimalist strategy”; decreasing 
patients trauma caused the procedure [23, 24].
Residual aortic regurgitation was found to be 
a strong predictor of late mortality, not only for 
severe but also for moderate insufficiency. How-
ever, the number of patients with severe residual 
paravalvular leak has decreased because a better 
patient and device selection, technique and device 
improvement and also because all operators are 
aware of the importance of this fact and make all the 
effort to fix it during the index procedure [25, 26].
Different subgroups of patients have been 
analyzed with the aim of finding those who can 
benefit more from the TAVR strategy. Among 
them, diabetics did better with TAVR, they had 
a lower 1-year mortality rate (18% vs. 27.4%, hazard 
ratio: 0.60; 95% confidence interval [CI]: 0.36–0.99; 
p = 0.04) with a lower incidence of dialysis > 30 days 
(0% vs. 6.1%; p = 0.003) without any differences 
in the stroke rate (PARTNER) [1].
Female gender showed lower 1-year mortal-
ity rate with TAVR in the PARTNER trial [27]. 
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Overweight patients also seem to benefit from 
TAVR vs. SAVR.
Concomitant mitral regurgitation is a frequent 
comorbid condition to SAS that usually tends to 
decrease after TAVR, but in some cases it does not 
occur and can also be a strong predictor of early 
(odds ratio [OR]: 1.49, 95% CI: 1.12–2.00; p = 
= 0.004; heterogeneity test = 0.006) and late (OR: 
1.44, 95% CI: 1.23–1.68; p < 0.001; heterogene-
ity test = 0.019) post-procedural mortality, which 
is higher in those patients who also have low left 
ventricular ejection fraction and low gradient: 
11.5% vs. 38.1%; adjusted hazard ratio: 3.27; 95% 
CI: 1.31–8.15; p = 0.011 and adjusted hazard ratio: 
4.62; p = 0.005 [18, 19]. Moreover, patients with 
SAS and mitral regurgitation included in the PART-
NER trial had a higher mortality rate at follow-up 
with isolated SAVR in comparison with TAVR 
without mitral valve repair or replacement [28].
With all this information, which is daily updated, 
we have enough data to support TAVR indication 
as the first strategy for patients with surgical con-
traindication and also to consider TAVR an excellent 
alternative to SAVR in patients at risk but who can 
be operated according to the Heart Team evaluation 
keeping in mind that SAVR perioperative mortality 
should not be higher than 3–4%. Thus, interme-
diate risk patients should be kept as a potential 
alternative, meanwhile the procedure is still highly 
expensive and RCTs in this regard are still not pre-
sented. However, some subgroup of intermediate 
risk patients should be now deeply discussed within 
the Heart Team, because some would benefit and 
should not face the risk of surgery.
In this regard, I would like to draw the atten-
tion to the octogenarians, especially those requir-
ing combined surgery (CABG + SAVR). These 
patients may benefit from percutaneous coronary 
intervention and staged TAVR.
Women, especially those with small body 
surface and small left ventricular outflow tract 
and severe overweight patients may be the second 
group for TAVR use expansion.
However, despite all this excitement, we 
have to be cautious about long-term durability 
(> 8–9 years), whereas long waiting list of high 
risk patients are still waiting health insurance au-
thorization, and some time dying, in many centers 
worldwide.
Finally, minimalist approach should not over-
pass the need of a multidisciplinary team and 
a high volume center so that, the RCT and big se-
ries’ outcomes are replicated to justify a still very 
expensive technique to be used in more patients.
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